Explore the world of psychedelic research

Papers | Trials | Reports | Events

Access our comprehensive database & reports to stay informed about
the latest developments as psychedelics move from trials to treatments

Rapid Effects of MDMA Administration on Self-Reported Personality Traits and Affect State: A Randomized, Placebo-Controlled Trial in Healthy Adults

This pre-registered randomized placebo-controlled study (n=34) investigates the effects of MDMA (100mg) administration on personality traits and affective states in healthy adults. While no statistical significance was found for the primary hypotheses, medium effect sizes were observed for increased Openness (d = 0.79) and Positive Affect (d = 0.51) 48 hours after MDMA administration compared to placebo.

Continue Reading

Category: Papers

Published: 2024-11-06

Acceptance as a possible link between past psychedelic experiences and psychological flexibility

This internet survey (n=629) examines how psychedelic experiences relate to psychological flexibility and mental well-being in classical psychedelic users. Network analysis shows psychological insight links to acceptance, while mediation analysis reveals psychological flexibility mediates the relationship between psychedelic use and well-being, suggesting experience quality matters more than frequency of use.

Continue Reading

Category: Papers

Published: 2024-11-06

Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing

This survey study (n=457) explores the relationship between dysfunctional attitudes and well-being in the context of psychedelic-assisted therapy. It finds that post-acute changes in these attitudes significantly influence well-being, with emotional breakthroughs having a greater impact than challenging or mystical experiences.

Continue Reading

Category: Papers

Published: 2024-11-06

The Impact of Antidepressant Discontinuation Prior to Treatment with Psilocybin for Treatment-Resistant Depression

This post hoc analysis (n=233) of a Phase II RCT investigates the impact of recent antidepressant discontinuation (n=156) on the efficacy of psilocybin in treating treatment-resistant depression (TRD). The study compares outcomes between participants who discontinued antidepressants during screening and those who entered the trial free of these medications, finding no significant relationship between antidepressant discontinuation and worsening depression severity or compromised psilocybin treatment efficacy.

Continue Reading

Category: Papers

Published: 2024-11-06

The non-hallucinogenic serotonin 1B receptor is necessary for the antidepressant-like effects of psilocybin in mice

This preprint mouse study (n=29) finds that the serotonin 1B receptor (5-HT1BR) is necessary for psilocybin's antidepressant and anxiolytic effects, independent of its hallucinogenic properties. Using transgenic mice lacking 5-HT1BR and network analysis, the study demonstrates that this receptor influences brain-wide activity patterns and mediates acute and persistent behavioural responses to psilocybin, suggesting a novel mechanism for psilocybin's therapeutic effects.

Continue Reading

Category: Papers

Published: 2024-11-06

Outcomes and physiologic responses associated with ketamine administration after traumatic brain injury in the United States and Canada: a retrospective analysis

This retrospective analysis (n=841) of the Prehospital Tranexamic Acid Use for Traumatic Brain Injury trial evaluates the effects of ketamine in subjects with traumatic brain injury (TBI). It finds no significant difference in mortality or disability between ketamine-exposed (15.5%) and unexposed subjects, though ketamine exposure was associated with fewer instances of elevated intracranial pressure and a lower increase in TBI protein biomarkers, despite a higher likelihood of seizure activity in the ketamine group.

Continue Reading

Category: Papers

Published: 2024-11-06

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

This pre-print, double-blind, placebo-controlled crossover study (n=22) investigates the neural effects of 2C-B (20mg) compared to psilocybin (15mg) and placebo using 7T resting-state functional MRI. The results reveal that both 2C-B and psilocybin reduce intra-network connectivity while enhancing between-network connectivity, with 2C-B showing less impact on certain connectivity measures but greater transmodal connectivity.

Continue Reading

Category: Papers

Published: 2024-11-06

Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey

This online survey (n=233) of autistic participants with high autism quotient scores examines their experiences with psychedelic drugs and perceived changes attributed to their most 'impactful' psychedelic experience. It finds that the majority of participants reported reductions in psychological distress (82%) and social anxiety (78%), and increases in social engagement (70%), while 20% reported undesirable effects such as increased anxiety.

Continue Reading

Category: Papers

Published: 2024-10-10

Complex slow waves radically reorganise human brain dynamics under 5-MeO-DMT

This preprint, naturalistic EEG study (n=29) examines the effects of inhaled synthetic 5-MeO-DMT (12mg) on brain activity in healthy individuals. It finds that 5-MeO-DMT radically reorganises low-frequency neural activity flows, making them incoherent, heterogeneous, and nonrecurring. It also causes broadband activity to exhibit slower, more stable, low-dimensional behaviour with increased energy barriers to rapid global shifts.

Continue Reading

Category: Papers

Published: 2024-10-10

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

This meta-analysis (2024, s=31) examines the correlation between subjective effects and therapeutic outcomes for ketamine (s=23, n=471) and psilocybin (s=8, n=183) in depression and substance use disorder (SUD) treatment. It finds modest mediating effects of subjective experiences on therapeutic outcomes, with psilocybin showing a stronger mediating effect (R² = 24%) compared to ketamine (R² = 5-10%), and a greater mediating effect observed in SUD compared to depression regardless of the substance used.

Continue Reading

Category: Papers

Published: 2024-10-10

Search

partners

Explore Blossom’s Resources

Interconnected & Contextualized Databases

Discover the most relevant papers, trials, events, companies, and people in our extensive collection of over 5,000 entries and 100,000 data points.

Explore Databases

Our interconnected databases allow you to uncover valuable insights and connections in psychedelic research.

Well-Researched Reports

Navigate the complex psychedelic landscape with our meticulously researched reports, covering 18 essential topics, 14 compounds, and 20 countries.

Explore Reports

Our reports provide a comprehensive overview of the current state and future potential of psychedelics.

Timely Insights

Stay informed about the most recent developments in psychedelic research and implementation with our timely articles and updates.

Explore Insights

Our insights cover a wide range of topics, from groundbreaking studies to regulatory changes and industry trends.

Are you new to psychedelics as medicine? Start with our overview →

Subscribe to The Bloom newsletter

Stay at the forefront of the psychedelic revolution with our weekly email, sent every Tuesday. Packed with the latest research breakthroughs, industry news, and actionable insights, The Bloom newsletter is your essential guide to the world of psychedelics.

Join a growing community of over 3,000 researchers, practitioners, and enthusiasts who rely on The Bloom for accurate, timely, and relevant information.

Stay up-to-date with psychedelic research

Free | Blossom Insider

Weekly psychedelic research newsletter
Unlimited browsing on Blossom
2000+ Research Papers (short summaries)

Join

Blossom Pro

Unlimited access for one account
Full reports & extended research summaries
Personal profile priority updates
chatBlossom (our chat interface, in development)

Learn More

Cancel anytime

Blossom Business

Unlimited access for up to ten accounts
All Pro membership benefits, Plus:
Company profile priority updates
Connect via API (show/remix our data on your platform)

Learn More

Cancel anytime

partners

“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”

Josh Hardman

Founder, Psychedelic Alpha

“The work that Floris and the Blossom team have done to document, organise and synthesise the emerging psychedelic research has helped me stay up to date with this fast-changing landscape. The Bloom newsletter and databases are indispensable resources for anyone who wants to understand the psychedelic science and medicine landscape.”

Zach Heighney

Founder, The Trip Report

partners

Explore Our Comprehensive Psychedelic Reports

Discover a wealth of knowledge in our comprehensive psychedelic reports.

“It is wonderful to receive the Bloom newsletter summarising the latest psychedelics research. With so many exciting studies in the psychedelic space, it can be hard to keep up!”

Anne Katrin Schlag

Acting CEO & Head of Research, Drug Science

“Blossom is my go-to resource for the latest in research. It’s the only site to which I refer people who want a comprehensive search for and thoroughgoing analysis of psychedelic studies and papers.”

Rick Strassman

Clinical Associate Professor of Psychiatry, University of New Mexico School of Medicine
Author, DMT: The Spirit Molecule

Embark on a Journey of Personal Transformation with FLO Coaching

FLO Coaching

FLO Coaching, our sister company, offers a personal touch to psychedelic-assisted growth, complementing Blossom’s mission to drive big-picture changes in the psychedelic space.

Founded by Floris, the creator of Blossom, and his wife, FLO Coaching provides one-on-one coaching sessions with psychedelic substances, all within the legal boundaries of The Netherlands. We create a safe and supportive space for you to explore your inner self, overcome obstacles, and grow in ways you never thought possible. At FLO Coaching, we combine cutting-edge research with a personalized approach, tailoring each session to your unique needs and goals.